What Inito does

Inito is a privately held health-diagnostics company that develops and sells an at-home, smartphone-connected fertility monitoring system. Its core product, the Inito Fertility Monitor, pairs a proprietary optical reader — either the legacy First Generation Reader (iOS-attached) or the newer InSight Wireless Reader (standalone, Wi-Fi, iOS and Android) — with disposable immunoassay test strips and a companion mobile app. The system quantitatively measures four reproductive hormones (LH, Estrogen, PdG, and FSH) on independent tracks using Inito's proprietary Spectral Mapping™ technology, which combines fluorescence and colorimetric imaging, and applies AI/ML trained on more than 40 million hormone data points to deliver personalized cycle interpretation and ovulation confirmation rather than the faint-line, population-average thresholds of conventional ovulation predictor kits. The platform is FDA-registered, validated in peer-reviewed journals (Nature Scientific Reports and Human Reproduction Open, both 2023), and supported by 20+ patents.

Inito generates revenue through a hardware-plus-consumable model: the Inito Starter Kit (reader + 15 test strips) is sold for $119 (launch price, down from $169) via the company's own e-commerce storefront and authorized retailers including Amazon, with HSA/FSA eligibility and US shipping; recurring revenue comes from $49, 15-strip refill packs available as one-time purchases or auto-reorder subscriptions. Its primary customer segment is women trying to conceive (TTC), with targeted use cases for PCOS, advanced maternal age (35+), irregular cycles, post-miscarriage recovery, and couples weighing IVF. Marketing is content-led and community-driven, anchored by an SEO-rich blog, use-case landing pages, an active Facebook support group, and endorsements from named OB/GYNs and reproductive endocrinologists.

Following a $29 million Series B in December 2025 (led by Bertelsmann India Investments with Fireside Ventures and Kyra Ventures), Inito is extending the platform from fertility into a broader at-home hormone and health diagnostics platform powered by AI-engineered synthetic antibodies, with planned new test types for pregnancy, menopause, thyroid, testosterone, and vitamins. The company is incorporated in the United States as Inito Health Inc. (Houston, TX legal entity) and operates across Bengaluru (India), Dubai (UAE), and London (UK), having raised approximately $45 million in total disclosed equity funding.

Name

Inito

Legal name

Inito Health Inc.

Website

https://inito.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

101–250 employees

Short description

Inito is a privately held health-diagnostics company that sells an FDA-registered, smartphone-connected at-home fertility monitor measuring four hormones (LH, Estrogen, PdG, FSH) via proprietary optical and AI technology, serving women trying to conceive globally through a hardware-plus-consumable subscription model.

Ownership category

akta.pro rank

Product category

At-Home Fertility Monitoring Devices

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151), Family Planning Centers (621410)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Fertility & Reproductive Endocrinology Telehealth (IVF/IUI, infertility evaluation) (HLALAHAA)

akta.pro secondary industries

Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection) (HLAHAOAF), Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Women’s Health & Fertility Tracking Devices (Ovulation/Temp Sensors, Pelvic Health Devices) (CRACAQAJ), Pregnancy & Prenatal Care Telehealth (OB tele-visits, prenatal monitoring) (HLALAHAC)

Keywords

• At-home fertility monitoring
• Hormone tracking devices
• Consumer medical diagnostics
• Smartphone-connected diagnostics
• Reproductive health technology

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. Hardware sales (Inito Fertility Monitor): One-time device purchase: Inito Starter Kit (InSight Wireless Reader + 15 Fertility Strips) at $119 (launch price, down from $169) or First Generation Reader kit at $99 (down from $149). HSA/FSA eligible.
2. Consumable test strip refills: Recurring purchase of 15-strip refill packs at $49 each, available both as one-time orders and as subscriptions with auto-reorder and discount pricing.
3. Promotional codes and discounts: Discount codes (e.g., INITONG offering $50 off) used to drive conversion; promotional cards and codes are subject to separately published terms.

Pricing tiers

Go-to-market motion5 records

Distribution channels3 records

Marketing channels8 records

Core offering

Inito designs, manufactures, and sells an at-home fertility monitoring ecosystem consisting of a proprietary smartphone-connected optical reader (InSight Wireless Reader or First Generation Reader), disposable immunoassay test strips that quantitatively measure four reproductive hormones (LH, Estrogen, PdG, FSH), and a companion mobile app that uses computer vision and AI to interpret results. The kit confirms ovulation and identifies a personalized six-day fertile window, with consumable strip refills sold on a subscription basis.

Product overview

Inito operates a single-product platform centered on the Inito Fertility Monitor, an FDA-registered medical device ecosystem consisting of two interchangeable hardware readers (the new InSight Wireless Reader™ and the legacy First Generation Reader), a consumable Inito Fertility Strips refill line (sold on subscription), the Inito Fertility & Ovulation mobile app for iOS and Android that runs the AI interpretation engine, and complementary offerings such as the InTemp Basal Thermometer and an opt-in Fertility Coach service. The hardware/software bundle uses Inito's proprietary Spectral Mapping™ computer-vision technology combined with on-device AI trained on more than 40 million hormone data points to deliver lab-grade quantitative measurements of four fertility hormones. Following the December 2025 Series B raise, Inito is expanding this core platform into a broader at-home hormone and health diagnostics platform powered by AI-engineered (synthetic) antibodies, with planned new test types for pregnancy, menopause, thyroid, testosterone, and vitamins.

Differentiator

Problem solved

Functional benefit

Products and services

• Inito Fertility Monitor (Starter Kit) The flagship at-home fertility monitoring kit that pairs a smartphone-connected reader with disposable test strips to quantitatively measure four hormones (LH, Estrogen, PdG, FSH) in urine and confirm ovulation within approximately 10 minutes; sold direct-to-consumer with HSA/FSA eligibility and free US shipping.
• InSight Wireless Reader New-generation wireless reader compatible with both iOS and Android, featuring enhanced precision via Inito Spectral Mapping technology and standalone Wi-Fi connectivity; pairs with the Inito app to display hormone values and personalized insights.
• First Generation Reader The original Inito reader that attaches physically to an iOS phone and functions only while connected; sold at a reduced legacy price compared to the InSight Wireless Reader.
• Inito Fertility Strips (15-strip refill pack) Single-use refill strips for use with either Inito reader; each strip simultaneously measures PdG (to confirm ovulation), Estrogen and LH (to predict the fertile window), and FSH (to track follicle growth); available as subscription refills at $49 per 15-strip pack.
• Inito Fertility & Ovulation App (iOS/Android) Companion mobile app that connects to the Inito reader, applies AI to interpret captured strip images, displays trend charts and personalized fertility insights, and lets users log symptoms, sex, medications, and pregnancy tests; no paid subscription required.
• InTemp Basal Thermometer Companion basal thermometer covered under the Inito 1-year limited warranty; sold as part of the Inito product ecosystem for users tracking basal body temperature alongside hormone data.
• Inito Fertility Coach Opt-in human coaching service referenced in the Terms of Service; users can elect to work with a Fertility Coach via email, chat, or calls to interpret their hormone data. Inito disclaims creation of any doctor-patient relationship through this service.

Quantifiable outcome

• Trusted by 200,000+ couples worldwide
• +5 more outcomes

Segments7 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability7 records

Feature6 records

Partnerships

Three partnerships are on record, tiered minor and core.

• DC AdvisoryminorImplementation/ SI/ Consulting Partner · 12 December 2025Served as financial advisor to Inito on its Series B fundraise from Bertelsmann India Investments, Fireside Ventures, and Kyra Ventures (transaction closed December 2025).
• Dr. Danielle Jones (Board-certified OB/GYN, @mamamdj)coreGTM or Marketing PartnerFeatured clinician endorser on the Inito homepage with 1.4M+ subscribers; provides video testimonial that Inito tracks multiple hormones in real time versus OPKs and BBT.
• Inito Clinical Advisors (Dr. Bradford Bopp, Dr. Robert Colver, Dr. Schehrezade Khan, Dr. Abhi Shahi, Dr. Prem Pillay, Dr. Sailaja M. Blackmon)coreStrategic or Co-development PartnerSix named clinical advisors (MDs / FRCS / FACS) listed on the About Inito page, lending medical expertise and credibility to product development and clinical positioning.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Emerging players

• Tempdrop: Tempdrop is a wearable basal body temperature sensor for cycle and fertility tracking. It serves an overlapping TTC audience with a different modality and price point, and competes for the same consumer wallet on the fertility tracking journey.
• Oura: Oura's smart ring tracks physiological markers and integrates with several women's health apps, including cycle and pregnancy features. While it does not directly measure hormones like Inito, it represents an emerging wearable-led path to fertility insights that could partially substitute for a dedicated monitor.
• Eli Health: Eli Health is an emerging at-home hormone testing startup building continuous and instant hormone monitoring products. Its mission to bring multi-hormone home diagnostics overlaps with Inito's announced expansion into broader hormone and biomarker testing.

Direct peers

• Mira: Mira sells a smartphone-connected hormone monitor and quantitative ovulation and fertility test strips. Like Inito, it positions on lab-grade multi-hormone measurement (LH, E3G, PdG) at home with AI-driven cycle insights, making it the closest direct competitor in the connected fertility monitor category.
• Proov: Proov is best known for the first at-home PdG ovulation confirmation test and has expanded into a multi-hormone test strip line. It overlaps directly with Inito's PdG-based ovulation confirmation and multi-hormone value proposition for the same trying-to-conceive customer.
• Modern Fertility (Ro): Modern Fertility, now part of Ro, sells at-home hormone tests and a fertility tracking experience targeted at women planning pregnancy or assessing fertility. It overlaps with Inito's expansion thesis into broader reproductive hormone diagnostics beyond a single monitor.
• Natural Cycles: Natural Cycles is an FDA-cleared app-driven fertility tracking product that combines basal body temperature with algorithm-based cycle predictions. It competes with Inito for the same TTC consumer but solves the problem with software and a thermometer rather than a hormone test strip, and is an obvious adjacent play for Inito to integrate or compete against.
• Ava: Ava sells a fertility tracking wearable bracelet and companion app that uses physiological signals to predict the fertile window. It targets the same TTC audience as Inito with a hardware-plus-subscription model, but with a different sensing modality (wrist-worn sensors vs urine test strips).

Broad incumbents

• Clearblue: Clearblue is the dominant incumbent brand of home ovulation and pregnancy tests, sold globally through retail. It competes with Inito on the entry-level OPK shelf and sets the price/availability benchmark Inito must beat to convert first-time buyers.
• First Response: First Response is a mass-market incumbent in home pregnancy and ovulation testing, with deep retail distribution. It competes with Inito in the broader 'track and confirm ovulation' use case and represents the low-cost retail alternative Inito must outperform on data quality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/groups/initofertility

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds9 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inito